Brown Capital Management LLC Has $1.82 Million Stake in Insulet Co. (NASDAQ:PODD)

Brown Capital Management LLC trimmed its holdings in shares of Insulet Co. (NASDAQ:PODD) by 58.8% in the third quarter, HoldingsChannel reports. The institutional investor owned 7,806 shares of the medical instruments supplier’s stock after selling 11,147 shares during the quarter. Brown Capital Management LLC’s holdings in Insulet were worth $1,817,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of PODD. Sei Investments Co. raised its position in shares of Insulet by 16.2% during the 1st quarter. Sei Investments Co. now owns 11,782 shares of the medical instruments supplier’s stock valued at $2,019,000 after acquiring an additional 1,639 shares during the last quarter. Bessemer Group Inc. boosted its position in shares of Insulet by 168.4% in the 1st quarter. Bessemer Group Inc. now owns 1,715 shares of the medical instruments supplier’s stock worth $294,000 after purchasing an additional 1,076 shares during the last quarter. National Bank of Canada FI grew its stake in shares of Insulet by 486.1% during the first quarter. National Bank of Canada FI now owns 96,734 shares of the medical instruments supplier’s stock worth $16,048,000 after purchasing an additional 80,230 shares during the period. Healthcare of Ontario Pension Plan Trust Fund increased its holdings in Insulet by 124.4% in the first quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 3,131 shares of the medical instruments supplier’s stock valued at $537,000 after purchasing an additional 1,736 shares during the last quarter. Finally, Natixis acquired a new position in Insulet in the first quarter valued at about $3,610,000.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on PODD shares. Morgan Stanley boosted their target price on Insulet from $234.00 to $317.00 and gave the stock an “overweight” rating in a research report on Monday, November 11th. Barclays boosted their price objective on shares of Insulet from $220.00 to $234.00 and gave the company an “equal weight” rating in a report on Monday, November 11th. Raymond James upped their target price on shares of Insulet from $213.00 to $260.00 and gave the company an “outperform” rating in a research note on Monday, October 14th. Piper Sandler lifted their price target on shares of Insulet from $230.00 to $285.00 and gave the stock an “overweight” rating in a research report on Tuesday, September 17th. Finally, Sanford C. Bernstein initiated coverage on shares of Insulet in a research report on Wednesday, November 6th. They issued an “outperform” rating and a $300.00 price objective for the company. Three research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. According to MarketBeat.com, Insulet presently has an average rating of “Moderate Buy” and an average price target of $253.27.

Insulet Stock Performance

Shares of Insulet stock opened at $266.58 on Thursday. The company has a debt-to-equity ratio of 1.21, a current ratio of 3.68 and a quick ratio of 2.80. The firm has a market cap of $18.70 billion, a price-to-earnings ratio of 45.65, a price-to-earnings-growth ratio of 4.01 and a beta of 1.22. The stock’s 50-day moving average is $240.09 and its 200-day moving average is $209.62. Insulet Co. has a one year low of $160.19 and a one year high of $279.40.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.